{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:32:21Z","timestamp":1744360341960,"version":"3.37.3"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>To retrospectively evaluate initial tumor necrosis factor inhibitor (TNFi) failure patients for clinical predictors of response to a 2nd TNFi in our 4282 rheumatoid arthritis (RA) patient database.<\/jats:p>\n            <jats:p>A cross-sectional retrospective manual chart review of the electronic health record (EHR) was performed on 322 \u201creal world\u201d RA patients who were prescribed 2 TNFis. Response to TNFi was determined by the treating provider who had real time Clinical Disease Activity Index (CDAI) scores to inform treatment decisions. Age, gender, body mass index (BMI), insurance provider, duration of disease, cyclic citrullinated peptide antibody (CCP) and rheumatoid factor (RF) positivity, concomitant disease modifying anti-rheumatic drug therapy, length of time between diagnosis and start of 1st and 2nd TNFi, transient efficacy of 1st TNFi (defined as response to TNFi at 3 months but later lost response), and reason for discontinuation of 1st TNFi were analyzed. A multivariable logistic regression model was used to model response to a 2nd TNFi.<\/jats:p>\n            <jats:p>Response proportions to the 2nd TNFi were greater in females (161\/223, 72.2% response female vs 41\/75, 54.7% male, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.01), those who began their 1st TNFi within 3 months of their RA diagnosis, and in RF+ patients (123\/170, 72.4% response seropositive vs 66\/110, 60.0% seronegative, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.03). The higher female response rate was independent of age, BMI, and seropositivity.<\/jats:p>\n            <jats:p>In RA patients who failed an initial TNFi, female patients and patients with RF+ were more likely to have a clinical response to a 2nd TNFi. In the absence of these predictors, stronger consideration for choosing a biologic with an alternative mechanism of action might be given when the 1st TNFi fails.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000021827","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T17:02:59Z","timestamp":1598461379000},"page":"e21827","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy predictors of a second tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis"],"prefix":"10.1097","volume":"99","author":[{"given":"Jennifer","family":"Reams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8449-8242","authenticated-orcid":false,"given":"Alfred","family":"Denio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American college of rheumatology guidelines for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Care Res"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1136\/annrheumdis-2014-205325","article-title":"Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2016.13512","article-title":"Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug","volume":"316","author":"Gottenberg","year":"2016","journal-title":"JAMA"},{"key":"R5-20230915","first-page":"192","article-title":"Treatment persistence and healthcare costs among patients with rheumatoid arthritis after a change in targeted therapy","volume":"11","author":"Bonafede","year":"2018","journal-title":"Am Health Drug Benefits"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/ard.2006.056937","article-title":"Sex: A major predictor of remission in early rheumatoid arthritis?","volume":"66","author":"Forslind","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R7-20230915","article-title":"Sex differences in the achievement of remission and low disease activity in rheumatoid arthritis","author":"Maynard","year":"2019","journal-title":"Arthritis Care Res"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.3899\/jrheum.091432","article-title":"Disease progression and treatment responses in the prospective DMARD-na\u00efve seropositive early rheumatoid arthritis cohort: Does gender matter?","volume":"37","author":"Jawaheer","year":"2010","journal-title":"J Rheumatol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/ard.2008.102244","article-title":"Influence of gender on assessments of disease activity and function in early rheumatoid arthritis in relation to radiographic joint damage","volume":"69","author":"Ahlmen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3899\/jrheum.110548","article-title":"Sex differences in response to anti-TNF therapy in early and established rheumatoid arthritis \u2013 Results from the longitudinal Danish DANBIO registry","volume":"39","author":"Jawaheer","year":"2012","journal-title":"J Rheumatol"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"e14181","DOI":"10.1097\/MD.0000000000014181","article-title":"Rheumatoid factor as a predictor of response to treatment with anti-TNF alpha drugs in patients with rheumatoid arthritis: results of a cohort study","volume":"98","author":"Santos-Moreno","year":"2019","journal-title":"Medicine"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"e89442","DOI":"10.1371\/journal.pone.0089442","article-title":"The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNF( agent treatment in patients with rheumatoid arthritis: a meta-analysis","volume":"9","author":"Lv","year":"2014","journal-title":"PLoS One"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"e000515","DOI":"10.1136\/rmdopen-2017-000515","article-title":"Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: Results from the \u2018ORA\u2019 registry","volume":"3","author":"Nourisson","year":"2017","journal-title":"RMD Open"},{"key":"R14-20230915","first-page":"452","article-title":"The \u2018Switch\u2019 study protocol: A randomized-controlled trial of switching to an alternative tumor-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug","volume":"15","author":"Coy","year":"2015","journal-title":"BMC Musculoskelet Disord"},{"key":"R15-20230915","first-page":"1","article-title":"Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT","volume":"22","author":"Brown","year":"2018","journal-title":"Health Technol Assess"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"e13013","DOI":"10.1111\/eci.13013","article-title":"Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings","volume":"48","author":"Iannone","year":"2018","journal-title":"Eur J Clin Invest"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:58:33Z","timestamp":1694825913000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":16,"journal-issue":{"issue":"35","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021827","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,8,28]]}}}